Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	ATP-dependent diacylglycerol kinase activity	DGKQ DGKI DGKD DGKH	5.32e-08	11	73	4	GO:0004143
GeneOntologyMolecularFunction	lipid kinase activity	DGKQ DGKI DGKD DGKH	1.50e-05	41	73	4	GO:0001727
GeneOntologyMolecularFunction	phosphopyruvate hydratase activity	ENO1 ENO3	7.87e-05	4	73	2	GO:0004634
GeneOntologyMolecularFunction	DNA-binding transcription factor activity, RNA polymerase II-specific	ZBTB7A ZNF280D PATZ1 ZNF280C ZBTB40 ZNF280B MAFF NR5A1 ZNF615 ZNF90 RFX7 ZBTB7B ENO1 ZNF639	5.23e-04	1412	73	14	GO:0000981
GeneOntologyMolecularFunction	RNA polymerase II transcription regulatory region sequence-specific DNA binding	ZBTB7A ZNF280D PATZ1 ZNF280C ZNF280B MAFF NR5A1 ZNF615 ZNF90 RFX7 ZBTB7B ENO1 SUV39H2 ZNF639	7.24e-04	1459	73	14	GO:0000977
GeneOntologyBiologicalProcess	lipid phosphorylation	DGKQ DGKI DGKD DGKH	4.68e-08	11	73	4	GO:0046834
GeneOntologyBiologicalProcess	diacylglycerol metabolic process	DGKQ DGKI DGKD DGKH	2.77e-06	28	73	4	GO:0046339
GeneOntologyBiologicalProcess	phosphatidic acid biosynthetic process	DGKQ DGKI DGKD DGKH	7.81e-06	36	73	4	GO:0006654
GeneOntologyBiologicalProcess	phosphatidic acid metabolic process	DGKQ DGKI DGKD DGKH	1.32e-05	41	73	4	GO:0046473
GeneOntologyBiologicalProcess	negative regulation of phagocytosis, engulfment	SIGLEC12 SIGLEC8	1.23e-04	5	73	2	GO:0060101
GeneOntologyCellularComponent	phosphopyruvate hydratase complex	ENO1 ENO3	7.38e-05	4	74	2	GO:0000015
Domain	ZF_DAG_PE_1	PRKD2 RASGRP1 DGKQ DGKI TNS2 DGKD DGKH	5.40e-09	64	73	7	PS00479
Domain	ZF_DAG_PE_2	PRKD2 RASGRP1 DGKQ DGKI TNS2 DGKD DGKH	5.40e-09	64	73	7	PS50081
Domain	C1	PRKD2 RASGRP1 DGKQ DGKI TNS2 DGKD DGKH	6.03e-09	65	73	7	SM00109
Domain	PE/DAG-bd	PRKD2 RASGRP1 DGKQ DGKI TNS2 DGKD DGKH	6.73e-09	66	73	7	IPR002219
Domain	DAGK_acc	DGKQ DGKI DGKD DGKH	4.43e-08	10	73	4	PF00609
Domain	Diacylglycerol_kin_accessory	DGKQ DGKI DGKD DGKH	4.43e-08	10	73	4	IPR000756
Domain	DAGKa	DGKQ DGKI DGKD DGKH	4.43e-08	10	73	4	SM00045
Domain	C1_1	PRKD2 RASGRP1 DGKQ DGKI DGKD DGKH	8.96e-08	57	73	6	PF00130
Domain	DAGKc	DGKQ DGKI DGKD DGKH	2.09e-07	14	73	4	SM00046
Domain	DUF4195	ZNF280D ZNF280C ZNF280B	2.29e-07	4	73	3	PF13836
Domain	DUF4195	ZNF280D ZNF280C ZNF280B	2.29e-07	4	73	3	IPR025243
Domain	Diacylglycerol_kinase_cat_dom	DGKQ DGKI DGKD DGKH	2.84e-07	15	73	4	IPR001206
Domain	DAGK_cat	DGKQ DGKI DGKD DGKH	2.84e-07	15	73	4	PF00781
Domain	DAGK	DGKQ DGKI DGKD DGKH	2.84e-07	15	73	4	PS50146
Domain	NAD/diacylglycerol_kinase	DGKQ DGKI DGKD DGKH	4.92e-07	17	73	4	IPR016064
Domain	ZINC_FINGER_C2H2_2	ZNF462 ZBTB7A ZNF280D PATZ1 ZNF280C ZBTB40 ZNF280B ZNF615 ZNF90 ZBTB7B ZNF541 ZNF639	4.29e-05	775	73	12	PS50157
Domain	ZINC_FINGER_C2H2_1	ZNF462 ZBTB7A ZNF280D PATZ1 ZNF280C ZBTB40 ZNF280B ZNF615 ZNF90 ZBTB7B ZNF541 ZNF639	4.40e-05	777	73	12	PS00028
Domain	Enolase_C	ENO1 ENO3	4.51e-05	3	73	2	PF00113
Domain	Enolase_N	ENO1 ENO3	4.51e-05	3	73	2	PF03952
Domain	Enolase	ENO1 ENO3	4.51e-05	3	73	2	IPR000941
Domain	Enolase_N	ENO1 ENO3	4.51e-05	3	73	2	SM01193
Domain	Enolase_C	ENO1 ENO3	4.51e-05	3	73	2	SM01192
Domain	Enolase_C	ENO1 ENO3	4.51e-05	3	73	2	IPR020810
Domain	Enolase_N	ENO1 ENO3	4.51e-05	3	73	2	IPR020811
Domain	Enolase_CS	ENO1 ENO3	4.51e-05	3	73	2	IPR020809
Domain	ENOLASE	ENO1 ENO3	4.51e-05	3	73	2	PS00164
Domain	Znf_C2H2-like	ZNF462 ZBTB7A ZNF280D PATZ1 ZNF280C ZBTB40 ZNF280B ZNF615 ZNF90 ZBTB7B ZNF541 ZNF639	5.55e-05	796	73	12	IPR015880
Domain	Znf_C2H2	ZNF462 ZBTB7A ZNF280D PATZ1 ZNF280C ZBTB40 ZNF280B ZNF615 ZNF90 ZBTB7B ZNF541 ZNF639	6.19e-05	805	73	12	IPR007087
Domain	ZnF_C2H2	ZNF462 ZBTB7A ZNF280D PATZ1 ZNF280C ZBTB40 ZNF280B ZNF615 ZNF90 ZBTB7B ZNF541 ZNF639	6.41e-05	808	73	12	SM00355
Domain	-	ENO1 ENO3	9.00e-05	4	73	2	3.30.390.10
Domain	Enolase_C-like	ENO1 ENO3	9.00e-05	4	73	2	IPR029065
Domain	-	ENO1 ENO3	9.00e-05	4	73	2	3.20.20.120
Domain	Enolase_N-like	ENO1 ENO3	9.00e-05	4	73	2	IPR029017
Domain	DDT	BAZ2A BAZ1B	1.50e-04	5	73	2	SM00571
Domain	WSD	BAZ2A BAZ1B	1.50e-04	5	73	2	PF15613
Domain	WHIM1	BAZ2A BAZ1B	1.50e-04	5	73	2	PF15612
Domain	DDT_dom	BAZ2A BAZ1B	1.50e-04	5	73	2	IPR018501
Domain	WHIM1_dom	BAZ2A BAZ1B	1.50e-04	5	73	2	IPR028942
Domain	WHIM2_dom	BAZ2A BAZ1B	1.50e-04	5	73	2	IPR028941
Domain	DDT	BAZ2A BAZ1B	2.24e-04	6	73	2	PS50827
Domain	-	DST MACF1	2.24e-04	6	73	2	3.90.1290.10
Domain	GAR	DST MACF1	2.24e-04	6	73	2	PS51460
Domain	-	DST MACF1	2.24e-04	6	73	2	3.30.920.20
Domain	GAS_dom	DST MACF1	2.24e-04	6	73	2	IPR003108
Domain	GAS2	DST MACF1	2.24e-04	6	73	2	PF02187
Domain	GAS2	DST MACF1	2.24e-04	6	73	2	SM00243
Domain	Plectin_repeat	DST MACF1	3.12e-04	7	73	2	IPR001101
Domain	Plectin	DST MACF1	3.12e-04	7	73	2	PF00681
Domain	PLEC	DST MACF1	3.12e-04	7	73	2	SM00250
Domain	zf-C2H2	ZNF462 ZBTB7A ZNF280D PATZ1 ZBTB40 ZNF615 ZNF90 ZBTB7B ZNF541 ZNF639	3.49e-04	693	73	10	PF00096
Domain	-	ZNF462 ZBTB7A PATZ1 ZBTB40 ZNF615 ZNF90 ZBTB7B ZNF541 ZNF639	1.28e-03	679	73	9	3.30.160.60
Domain	Znf_C2H2/integrase_DNA-bd	ZNF462 ZBTB7A PATZ1 ZBTB40 ZNF615 ZNF90 ZBTB7B ZNF541 ZNF639	1.49e-03	694	73	9	IPR013087
Domain	BTB	ZBTB7A PATZ1 ZBTB40 ZBTB7B	1.73e-03	131	73	4	PF00651
Domain	AT_hook	BAZ2A PATZ1	1.75e-03	16	73	2	PF02178
Domain	IGc2	SIGLEC12 SIGLEC8 VSIG1 KDR LRIT1	2.27e-03	235	73	5	SM00408
Domain	Ig_sub2	SIGLEC12 SIGLEC8 VSIG1 KDR LRIT1	2.27e-03	235	73	5	IPR003598
Domain	DAG/PE-bd	PRKD2 RASGRP1	3.02e-03	21	73	2	IPR020454
Domain	BTB	ZBTB7A PATZ1 ZBTB40 ZBTB7B	3.57e-03	160	73	4	PS50097
Domain	Actinin_actin-bd_CS	DST MACF1	3.61e-03	23	73	2	IPR001589
Domain	Spectrin	DST MACF1	3.61e-03	23	73	2	PF00435
Domain	ACTININ_2	DST MACF1	3.61e-03	23	73	2	PS00020
Domain	ACTININ_1	DST MACF1	3.61e-03	23	73	2	PS00019
Domain	Bromodomain_CS	BAZ2A BAZ1B	4.61e-03	26	73	2	IPR018359
Domain	AT_hook	BAZ2A PATZ1	4.96e-03	27	73	2	SM00384
Domain	AT_hook_DNA-bd_motif	BAZ2A PATZ1	4.96e-03	27	73	2	IPR017956
Domain	BTB	ZBTB7A PATZ1 ZBTB40 ZBTB7B	5.42e-03	180	73	4	SM00225
Domain	Spectrin_repeat	DST MACF1	5.71e-03	29	73	2	IPR002017
Domain	V-set	SIGLEC12 SIGLEC8 VSIG1 KDR	5.85e-03	184	73	4	PF07686
Domain	BTB/POZ_dom	ZBTB7A PATZ1 ZBTB40 ZBTB7B	5.96e-03	185	73	4	IPR000210
Domain	ZF_PHD_2	RAG2 BAZ2A BAZ1B	6.13e-03	95	73	3	PS50016
Domain	ZF_PHD_1	RAG2 BAZ2A BAZ1B	6.31e-03	96	73	3	PS01359
Domain	SKP1/BTB/POZ	ZBTB7A PATZ1 ZBTB40 ZBTB7B	6.42e-03	189	73	4	IPR011333
Domain	HMGI/Y_DNA-bd_CS	BAZ2A PATZ1	6.51e-03	31	73	2	IPR000637
Domain	Ig_I-set	SIGLEC12 SIGLEC8 KDR LRIT1	6.54e-03	190	73	4	IPR013098
Domain	ig	SIGLEC12 SIGLEC8 KDR LRIT1	6.54e-03	190	73	4	PF00047
Pathway	REACTOME_EFFECTS_OF_PIP2_HYDROLYSIS	RASGRP1 DGKQ DGKI DGKD DGKH	4.26e-08	27	52	5	M12123
Pathway	REACTOME_EFFECTS_OF_PIP2_HYDROLYSIS	DGKQ DGKI DGKD DGKH	1.97e-06	25	52	4	MM14511
Pathway	KEGG_GLYCEROLIPID_METABOLISM	DGKQ DGKI DGKD DGKH	3.08e-05	49	52	4	M15902
Pathway	KEGG_PHOSPHATIDYLINOSITOL_SIGNALING_SYSTEM	DGKQ DGKI DGKD DGKH	1.74e-04	76	52	4	M9052
Pathway	KEGG_GLYCEROPHOSPHOLIPID_METABOLISM	DGKQ DGKI DGKD DGKH	1.83e-04	77	52	4	M9131
Pathway	REACTOME_PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION	RASGRP1 DGKQ DGKI APLP2 DGKD DGKH	3.49e-04	257	52	6	MM15454
Pathway	REACTOME_PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION	RASGRP1 DGKQ DGKI APLP2 DGKD DGKH	3.79e-04	261	52	6	M1077
Pubmed	Diacylglycerol kinase delta regulates protein kinase C and epidermal growth factor receptor signaling.	DGKQ DGKI DGKD DGKH	6.51e-09	11	75	4	17021016
Pubmed	The Transcription Factor MAZR/PATZ1 Regulates the Development of FOXP3+ Regulatory T Cells.	RAG2 PATZ1 ZBTB7B	9.63e-09	3	75	3	31875552
Pubmed	Evaluations of the selectivities of the diacylglycerol kinase inhibitors R59022 and R59949 among diacylglycerol kinase isozymes using a new non-radioactive assay method.	DGKQ DGKD DGKH	9.63e-09	3	75	3	23949095
Pubmed	Resolution of cell fate decisions revealed by single-cell gene expression analysis from zygote to blastocyst.	ZNF462 ZBTB7A GGNBP2 ZNF280D BAZ2A PATZ1 ZNF280C BAZ1B UNK ZNF280B ZBTB7B ZNF639	1.56e-07	808	75	12	20412781
Pubmed	A human skeletal muscle interactome centered on proteins involved in muscular dystrophies: LGMD interactome.	ZNF462 DST DTNA ZBTB40 MACF1 DGKD FHL1 ENO1 ENO3	1.26e-06	497	75	9	23414517
Pubmed	Identification and characterization of two splice variants of human diacylglycerol kinase eta.	DGKD DGKH	4.59e-06	2	75	2	12810723
Pubmed	Molecular cloning of a novel diacylglycerol kinase isozyme with a pleckstrin homology domain and a C-terminal tail similar to those of the EPH family of protein-tyrosine kinases.	DGKQ DGKD	4.59e-06	2	75	2	8626538
Pubmed	The zinc finger transcription factor Zbtb7b represses CD8-lineage gene expression in peripheral CD4+ T cells.	RAG2 ZBTB7B	4.59e-06	2	75	2	19062319
Pubmed	Acf7 (MACF) is an actin and microtubule linker protein whose expression predominates in neural, muscle, and lung development.	DST MACF1	4.59e-06	2	75	2	11002341
Pubmed	Transgenic expression of RasGRP1 induces the maturation of double-negative thymocytes and enhances the production of CD8 single-positive thymocytes.	RAG2 RASGRP1	4.59e-06	2	75	2	12538669
Pubmed	Deregulated expression of RasGRP1 initiates thymic lymphomagenesis independently of T-cell receptors.	RAG2 RASGRP1	4.59e-06	2	75	2	15829980
Pubmed	Differential expression of muscle-specific enolase in embryonic and fetal myogenic cells during mouse development.	ENO1 ENO3	4.59e-06	2	75	2	2090519
Pubmed	VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer.	KLRK1 KDR	4.59e-06	2	75	2	26909862
Pubmed	Mania- and anxiety-like behavior and impaired maternal care in female diacylglycerol kinase eta and iota double knockout mice.	DGKI DGKH	4.59e-06	2	75	2	30985063
Pubmed	Molecules in focus: diacylglycerol kinase.	DGKQ DGKH	4.59e-06	2	75	2	9438377
Pubmed	The hcKrox gene family regulates multiple extracellular matrix genes.	ZBTB7A ZBTB7B	4.59e-06	2	75	2	11691585
Pubmed	Zbtb7a and Zbtb7b: Opening naïve loci to reprogram ESCs.	ZBTB7A ZBTB7B	4.59e-06	2	75	2	33627571
Pubmed	Biochemical characterization of the mouse muscle-specific enolase: developmental changes in electrophoretic variants and selective binding to other proteins.	ENO1 ENO3	4.59e-06	2	75	2	9169614
Pubmed	Fibre-type distribution and subcellular localisation of alpha and beta enolase in mouse striated muscle.	ENO1 ENO3	4.59e-06	2	75	2	11229603
Pubmed	The in vivo Interaction Landscape of Histones H3.1 and H3.3.	ZNF462 GTF3C1 ZNF280D BAZ2A ZNF280C WRN ZBTB40 BAZ1B SUV39H2	6.47e-06	608	75	9	36089195
Pubmed	Mutations of the Transcriptional Corepressor ZMYM2 Cause Syndromic Urinary Tract Malformations.	ZNF462 GTF3C1 ZNF280D ZNF280C ZNF280B	7.81e-06	125	75	5	32891193
Pubmed	ZBTB20 is crucial for the specification of a subset of callosal projection neurons and astrocytes in the mammalian neocortex.	ZBTB7A PATZ1 ZBTB40 ZBTB7B	1.08e-05	63	75	4	34351428
Pubmed	Expression of the mouse Macf2 gene during inner ear development.	DST MACF1	1.37e-05	3	75	2	12399109
Pubmed	cAMP-stimulated transcription of DGKθ requires steroidogenic factor 1 and sterol regulatory element binding protein 1.	DGKQ NR5A1	1.37e-05	3	75	2	23610160
Pubmed	The zinc-finger transcription factor MAZR regulates iNKT cell subset differentiation.	PATZ1 ZBTB7B	1.37e-05	3	75	2	31065747
Pubmed	Targeted Sos1 deletion reveals its critical role in early T-cell development.	RAG2 RASGRP1	1.37e-05	3	75	2	21746917
Pubmed	Disregulated expression of the transcription factor ThPOK during T-cell development leads to high incidence of T-cell lymphomas.	RAG2 ZBTB7B	1.37e-05	3	75	2	26056302
Pubmed	Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.	BAZ2A ZNF280C BAZ1B ENO1	1.84e-05	72	75	4	31248990
Pubmed	A genome-wide screen to identify transcription factors expressed in pelvic Ganglia of the lower urinary tract.	ZNF462 GTF3C1 BAZ2A BAZ1B MACF1 MAFF FHL1 ZBTB7B ZNF639	2.19e-05	709	75	9	22988430
Pubmed	Studies on the Detection, Expression, Glycosylation, Dimerization, and Ligand Binding Properties of Mouse Siglec-E.	SIGLEC12 SIGLEC8	2.75e-05	4	75	2	27920204
Pubmed	Early murine T-lymphocyte activation is accompanied by a switch from N-Glycolyl- to N-acetyl-neuraminic acid and generation of ligands for siglec-E.	SIGLEC12 SIGLEC8	2.75e-05	4	75	2	21835922
Pubmed	Human-specific elimination of epithelial Siglec-XII suppresses the risk of inflammation-driven colorectal cancers.	SIGLEC12 SIGLEC8	2.75e-05	4	75	2	38990656
Pubmed	Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity.	SIGLEC12 SIGLEC8	2.75e-05	4	75	2	34155121
Pubmed	Polysialic acid and Siglec-E orchestrate negative feedback regulation of microglia activation.	SIGLEC12 SIGLEC8	2.75e-05	4	75	2	32725371
Pubmed	The ability of Sos1 to oligomerize the adaptor protein LAT is separable from its guanine nucleotide exchange activity in vivo.	RAG2 RASGRP1	2.75e-05	4	75	2	24222714
Pubmed	Leishmania donovani Utilize Sialic Acids for Binding and Phagocytosis in the Macrophages through Selective Utilization of Siglecs and Impair the Innate Immune Arm.	SIGLEC12 SIGLEC8	2.75e-05	4	75	2	27494323
Pubmed	Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response.	SIGLEC12 SIGLEC8	2.75e-05	4	75	2	37460871
Pubmed	Group B Streptococcus engages an inhibitory Siglec through sialic acid mimicry to blunt innate immune and inflammatory responses in vivo.	SIGLEC12 SIGLEC8	2.75e-05	4	75	2	24391502
Pubmed	The receptor binding domain of SARS-CoV-2 Omicron subvariants targets Siglec-9 to decrease its immunogenicity by preventing macrophage phagocytosis.	SIGLEC12 SIGLEC8	2.75e-05	4	75	2	38454157
Pubmed	Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.	SIGLEC12 SIGLEC8	2.75e-05	4	75	2	30130255
Pubmed	Nuclear diacylglycerol kinase-theta is activated in response to alpha-thrombin.	DGKQ DGKD	2.75e-05	4	75	2	11309392
Pubmed	Dual actions of group B Streptococcus capsular sialic acid provide resistance to platelet-mediated antimicrobial killing.	SIGLEC12 SIGLEC8	2.75e-05	4	75	2	30910970
Pubmed	A Moonlighting Human Protein Is Involved in Mitochondrial Import of tRNA.	ENO1 ENO3	2.75e-05	4	75	2	25918939
Pubmed	O-Acetylation of Capsular Polysialic Acid Enables Escherichia coli K1 Escaping from Siglec-Mediated Innate Immunity and Lysosomal Degradation of E. coli-Containing Vacuoles in Macrophage-Like Cells.	SIGLEC12 SIGLEC8	2.75e-05	4	75	2	34878295
Pubmed	Siglec receptors impact mammalian lifespan by modulating oxidative stress.	SIGLEC12 SIGLEC8	2.75e-05	4	75	2	25846707
Pubmed	Cloning and characterization of mouse ACF7, a novel member of the dystonin subfamily of actin binding proteins.	DST MACF1	2.75e-05	4	75	2	8954775
Pubmed	Immunosuppressive Siglec-E ligands on mouse aorta are up-regulated by LPS via NF-κB pathway.	SIGLEC12 SIGLEC8	2.75e-05	4	75	2	31918287
Pubmed	Sialylated ligands on pathogenic Trypanosoma cruzi interact with Siglec-E (sialic acid-binding Ig-like lectin-E).	SIGLEC12 SIGLEC8	2.75e-05	4	75	2	19552697
Pubmed	Targeting the Siglec-sialic acid axis promotes antitumor immune responses in preclinical models of glioblastoma.	SIGLEC12 SIGLEC8	2.75e-05	4	75	2	37467314
Pubmed	Polysialic acid promotes remyelination in cerebellar slice cultures by Siglec-E-dependent modulation of microglia polarization.	SIGLEC12 SIGLEC8	2.75e-05	4	75	2	37492129
Pubmed	Ablation of Siglec-E augments brain inflammation and ischemic injury.	SIGLEC12 SIGLEC8	2.75e-05	4	75	2	35858866
Pubmed	The human sialic acid-binding immunoglobulin-like lectin Siglec-9 and its murine homolog Siglec-E control osteoclast activity and bone resorption.	SIGLEC12 SIGLEC8	2.75e-05	4	75	2	33007530
Pubmed	Involvement of sulfates from cruzipain, a major antigen of Trypanosoma cruzi, in the interaction with immunomodulatory molecule Siglec-E.	SIGLEC12 SIGLEC8	2.75e-05	4	75	2	26047932
Pubmed	A STAT3-dependent transcriptional circuitry inhibits cytotoxic gene expression in T cells.	ZBTB7A ZBTB7B	2.75e-05	4	75	2	29180433
Pubmed	Siglec genes confer resistance to systemic lupus erythematosus in humans and mice.	SIGLEC12 SIGLEC8	2.75e-05	4	75	2	29503442
Pubmed	Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.	SIGLEC12 SIGLEC8	2.75e-05	4	75	2	25225409
Pubmed	Modulation of embryonic and muscle-specific enolase gene products in the developing mouse hindlimb.	ENO1 ENO3	2.75e-05	4	75	2	1280607
Pubmed	The SOX2-interactome in brain cancer cells identifies the requirement of MSI2 and USP9X for the growth of brain tumor cells.	ZNF462 ZBTB7A PATZ1 MACF1 IPO4 ENOX2	3.39e-05	282	75	6	23667531
Pubmed	Siglec-E promotes β2-integrin-dependent NADPH oxidase activation to suppress neutrophil recruitment to the lung.	SIGLEC12 SIGLEC8	4.57e-05	5	75	2	24895121
Pubmed	Microglial CD33-related Siglec-E inhibits neurotoxicity by preventing the phagocytosis-associated oxidative burst.	SIGLEC12 SIGLEC8	4.57e-05	5	75	2	24227736
Pubmed	A soluble form of Siglec-9 provides an antitumor benefit against mammary tumor cells expressing MUC1 in transgenic mice.	SIGLEC12 SIGLEC8	4.57e-05	5	75	2	24924635
Pubmed	Group 3 innate lymphocytes make a distinct contribution to type 17 immunity in bladder defence.	RAG2 IL22RA1	4.57e-05	5	75	2	35845169
Pubmed	Binding of the sialic acid-binding lectin, Siglec-9, to the membrane mucin, MUC1, induces recruitment of β-catenin and subsequent cell growth.	SIGLEC12 SIGLEC8	4.57e-05	5	75	2	24045940
Pubmed	Siglec-E is up-regulated and phosphorylated following lipopolysaccharide stimulation in order to limit TLR-driven cytokine production.	SIGLEC12 SIGLEC8	4.57e-05	5	75	2	19933851
Pubmed	Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection.	KLRK1 RAG2	4.57e-05	5	75	2	25745066
Pubmed	SEDLIN forms homodimers: characterisation of SEDLIN mutations and their interactions with transcription factors MBP1, PITX1 and SF1.	NR5A1 ENO1	4.57e-05	5	75	2	20498720
Pubmed	Siglec-9 modulated IL-4 responses in the macrophage cell line RAW264.	SIGLEC12 SIGLEC8	4.57e-05	5	75	2	26540411
Pubmed	Siglec-E Negatively Regulates the Activation of TLR4 by Controlling Its Endocytosis.	SIGLEC12 SIGLEC8	4.57e-05	5	75	2	27619995
Pubmed	A novel family of bromodomain genes.	BAZ2A BAZ1B	4.57e-05	5	75	2	10662543
Pubmed	Transcriptional reprogramming of mature CD4⁺ helper T cells generates distinct MHC class II-restricted cytotoxic T lymphocytes.	PATZ1 ZBTB7B	4.57e-05	5	75	2	23334788
Pubmed	Probing the cis interactions of the inhibitory receptor Siglec-7 with alpha2,8-disialylated ligands on natural killer cells and other leukocytes using glycan-specific antibodies and by analysis of alpha2,8-sialyltransferase gene expression.	SIGLEC12 SIGLEC8	4.57e-05	5	75	2	16857734
Pubmed	The transcription factors Thpok and LRF are necessary and partly redundant for T helper cell differentiation.	ZBTB7A ZBTB7B	4.57e-05	5	75	2	23041065
Pubmed	The zinc finger transcription factor Th-POK regulates CD4 versus CD8 T-cell lineage commitment.	ZBTB7A ZBTB7B	4.57e-05	5	75	2	15729333
Pubmed	The zinc-finger protein MAZR is part of the transcription factor network that controls the CD4 versus CD8 lineage fate of double-positive thymocytes.	PATZ1 ZBTB7B	4.57e-05	5	75	2	20383150
Pubmed	The prognostic impact of SIGLEC5-induced impairment of CD8+ T cell activation in sepsis.	SIGLEC12 SIGLEC8	4.57e-05	5	75	2	37890368
Pubmed	Gonadal sex reversal in mutant Dax1 XY mice: a failure to upregulate Sox9 in pre-Sertoli cells.	DTNA SOSTDC1 NR5A1	6.53e-05	36	75	3	15944188
Pubmed	Cathepsin X cleaves the C-terminal dipeptide of alpha- and gamma-enolase and impairs survival and neuritogenesis of neuronal cells.	ENO1 ENO3	6.84e-05	6	75	2	19433310
Pubmed	Control of Regulatory T Cell Differentiation by the Transcription Factors Thpok and LRF.	ZBTB7A ZBTB7B	6.84e-05	6	75	2	28754678
Pubmed	Development of promyelocytic leukemia zinc finger-expressing innate CD4 T cells requires stronger T-cell receptor signals than conventional CD4 T cells.	RASGRP1 ZBTB7B	6.84e-05	6	75	2	22988097
Pubmed	Activation of the gene encoding the glycolytic enzyme beta-enolase during early myogenesis precedes an increased expression during fetal muscle development.	ENO1 ENO3	6.84e-05	6	75	2	1525038
Pubmed	Siglec-E is a negative regulator of acute pulmonary neutrophil inflammation and suppresses CD11b β2-integrin-dependent signaling.	SIGLEC12 SIGLEC8	6.84e-05	6	75	2	23315163
Pubmed	NK cells use NKG2D to recognize a mouse renal cancer (Renca), yet require intercellular adhesion molecule-1 expression on the tumor cells for optimal perforin-dependent effector function.	KLRK1 RAG2	6.84e-05	6	75	2	16888019
Pubmed	miR-24 suppression of POZ/BTB and AT-hook-containing zinc finger protein 1 (PATZ1) protects endothelial cell from diabetic damage.	PATZ1 ZBTB7B	6.84e-05	6	75	2	27983982
Pubmed	Regulatory T cells suppress the formation of potent KLRK1 and IL-7R expressing effector CD8 T cells by limiting IL-2.	KLRK1 RAG2	6.84e-05	6	75	2	36705564
Pubmed	Cyclic AMP-stimulated interaction between steroidogenic factor 1 and diacylglycerol kinase theta facilitates induction of CYP17.	DGKQ NR5A1	6.84e-05	6	75	2	17664281
Pubmed	Molecular cloning of MIS, a myeloid inhibitory siglec, that binds protein-tyrosine phosphatases SHP-1 and SHP-2.	SIGLEC12 SIGLEC8	6.84e-05	6	75	2	11278955
Pubmed	In vivo CRISPR screening identifies BAZ2 chromatin remodelers as druggable regulators of mammalian liver regeneration.	RAG2 BAZ2A	6.84e-05	6	75	2	35090595
Pubmed	WSTF-ISWI chromatin remodeling complex targets heterochromatic replication foci.	BAZ2A BAZ1B	6.84e-05	6	75	2	11980720
Pubmed	A ThPOK-LRF transcriptional node maintains the integrity and effector potential of post-thymic CD4+ T cells.	ZBTB7A ZBTB7B	6.84e-05	6	75	2	25129370
Pubmed	Agrin has a pathological role in the progression of oral cancer.	IPO4 FHL1 ZBTB7B ENO1 ENO3	6.93e-05	197	75	5	29872149
Pubmed	New genetic associations detected in a host response study to hepatitis B vaccine.	SIGLEC12 RAG2 GIMAP8 SIGLEC8 MACF1 PTGER4 IL22RA1 RSL24D1 LRIT1	7.00e-05	824	75	9	20237496
Pubmed	The RNA-mediated estrogen receptor α interactome of hormone-dependent human breast cancer cell nuclei.	ZBTB7A GGNBP2 DST BAZ2A WRN BAZ1B WHAMM UNK MACF1 APLP2 IPO4 ZBTB7B	8.19e-05	1497	75	12	31527615
Pubmed	mSiglec-E, a novel mouse CD33-related siglec (sialic acid-binding immunoglobulin-like lectin) that recruits Src homology 2 (SH2)-domain-containing protein tyrosine phosphatases SHP-1 and SHP-2.	SIGLEC12 SIGLEC8	9.57e-05	7	75	2	11171044
Pubmed	The murine inhibitory receptor mSiglec-E is expressed broadly on cells of the innate immune system whereas mSiglec-F is restricted to eosinophils.	SIGLEC12 SIGLEC8	9.57e-05	7	75	2	15048729
Pubmed	[Functions and molecular evolution of Siglecs, a family of sialic acid receptor proteins].	SIGLEC12 SIGLEC8	9.57e-05	7	75	2	18453149
Pubmed	Paired Siglec receptors generate opposite inflammatory responses to a human-specific pathogen.	SIGLEC12 SIGLEC8	9.57e-05	7	75	2	28100677
Pubmed	H4K20me0 recognition by BRCA1-BARD1 directs homologous recombination to sister chromatids.	ZBTB7A DST GTF3C1 BAZ2A PATZ1 WRN BAZ1B MAFF RFX7 ZBTB7B RSL24D1	1.00e-04	1294	75	11	30804502
Pubmed	Broad and direct interaction between TLR and Siglec families of pattern recognition receptors and its regulation by Neu1.	SIGLEC12 SIGLEC8	1.27e-04	8	75	2	25187624
Pubmed	Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production.	RAG2 PTGER4	1.27e-04	8	75	2	19098906
Pubmed	Distinct functions for the transcription factors GATA-3 and ThPOK during intrathymic differentiation of CD4(+) T cells.	RAG2 ZBTB7B	1.27e-04	8	75	2	18776904
Interaction	CBX5 interactions	ZNF462 ZBTB7A ZNF280D ZNF280C UNK KDR ZBTB7B ENO1 SUV39H2	4.30e-06	356	71	9	int:CBX5
Interaction	DEDD interactions	USP22 GTF3C1 APLP2 ENO1	4.72e-06	32	71	4	int:DEDD
Interaction	CBX3 interactions	ZNF462 GTF3C1 ZNF280D BAZ2A ZNF280C BAZ1B UNK MACF1 ZNF615 ZBTB7B SUV39H2	1.50e-05	646	71	11	int:CBX3
GeneFamily	EF-hand domain containing\|Diacylglycerol kinases	DGKQ DGKI DGKD DGKH	1.59e-08	10	55	4	1178
GeneFamily	EF-hand domain containing\|Plakins	DST MACF1	2.51e-04	8	55	2	939
GeneFamily	Zinc fingers C2H2-type\|ZF class homeoboxes and pseudogenes	ZNF462 ZBTB7A PATZ1 ZBTB40 ZNF615 ZNF90 ZBTB7B ZNF541 ZNF639	2.89e-04	718	55	9	28
GeneFamily	Basic leucine zipper proteins\|BTB domain containing	ZBTB7A PATZ1 ZBTB40 ZBTB7B	7.34e-04	134	55	4	861
GeneFamily	Adenosine receptors\|V-set domain containing	SIGLEC12 SIGLEC8 VSIG1 KDR	1.52e-03	163	55	4	590
GeneFamily	CD molecules\|C2-set domain containing\|Sialic acid binding Ig like lectins	SIGLEC12 SIGLEC8	3.26e-03	28	55	2	745
GeneFamily	Zinc fingers CCCH-type	UNK ZC3H3	5.07e-03	35	55	2	73
Coexpression	GSE27241_WT_VS_RORGT_KO_TH17_POLARIZED_CD4_TCELL_TREATED_WITH_DIGOXIN_UP	GTF3C1 BAZ2A WRN ZBTB40 BAZ1B MACF1 RFX7	8.58e-07	180	75	7	M8239
ToppCell	facs-Thymus-nan-3m\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PRKD2 RAG2 RASGRP1 ZNF280D PATZ1 DGKD	9.35e-07	194	75	6	f1661f9f2439fca5c1012c693b0744c4e3b90a9b
ToppCell	facs-Thymus-nan\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PRKD2 RAG2 RASGRP1 ZNF280D PATZ1 DGKD	9.35e-07	194	75	6	cda1b197efb199330ea7ab25a7cee22cae22589d
ToppCell	facs-Thymus-nan-3m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PRKD2 RAG2 RASGRP1 ZNF280D PATZ1 DGKD	9.35e-07	194	75	6	66c056232ac216780acf4cc8ea325bd8ed1909c9
ToppCell	LPS_IL1RA-Endothelial-Endothelial-Gen_Cap\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	HEG1 DST USP22 MACF1 KDR DGKH	1.12e-06	200	75	6	dccec522ab0d7fff62ad6273b02aa9022dbbb8eb
ToppCell	LPS_anti-TNF-Endothelial-Endothelial-Gen_Cap\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	HEG1 DST USP22 MACF1 KDR DGKH	1.12e-06	200	75	6	a2b9d1cd291d17abddc3ee2e242121412c864b8b
ToppCell	Transplant_Alveoli_and_parenchyma-Epithelial-Type_1_alveolar\|Epithelial / Tissue, Lineage and Cell class of Lung Cells from 10X	HEG1 DST ASIC1 DGKI ABCA8	7.54e-06	160	75	5	58ed3a074932ccc951e07868dfdc61b99ae1cc2b
ToppCell	facs-Marrow-T-cells-3m-Lymphocytic\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KLRK1 RASGRP1 GIMAP8 MACF1 DGKD	1.48e-05	184	75	5	b12fb85a064f715a4f0ada1df8e422c359b573cf
ToppCell	facs-Marrow-T-cells-3m\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KLRK1 RASGRP1 GIMAP8 MACF1 DGKD	1.52e-05	185	75	5	e1fd0a807def8c2127194108b1a30c6de7024292
ToppCell	Control-Fibroblasts-Alveolar_FB\|Control / group, cell type (main and fine annotations)	DST DTNA MACF1 FHL1 ABCA8	1.60e-05	187	75	5	92d468dde81125d51daf7abd4703741abe1ab91c
ToppCell	nucseq-Mesenchymal-Fibroblastic-Fibroblastic_2-AF1\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	DST DTNA MACF1 FHL1 ABCA8	1.77e-05	191	75	5	6688cee34beee4f151ac17fccbc9c26a9aad72e1
ToppCell	nucseq-Mesenchymal-Fibroblastic-Fibroblastic_2\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	DST DTNA MACF1 FHL1 ABCA8	1.82e-05	192	75	5	99ce9e3c4c50cf64ebb62145f2b5420efa0db309
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro1_(4)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	DST DTNA MACF1 FHL1 ABCA8	1.87e-05	193	75	5	9f69edc97b868d23998abc98928a2e89a885ef8a
ToppCell	facs-Thymus-nan-3m-Lymphocytic-DN_to_DP_transition_(most_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PRKD2 RAG2 RASGRP1 ZNF280D PATZ1	1.87e-05	193	75	5	a6a864644e1b80b7417ea0a27281e79068a3fd3d
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro1_(4)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	DST DTNA MACF1 FHL1 ABCA8	1.91e-05	194	75	5	71d3c7448b1734de54187f902f65649f9283bd4c
ToppCell	LPS-IL1RA-Endothelial-Endothelial-Gen_Cap\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	HEG1 DST MACF1 KDR DGKH	1.91e-05	194	75	5	0b9cd96fa0b616da7cc90e92ff71157e9bba518f
ToppCell	ASK440-Endothelial-Endothelium\|ASK440 / Donor, Lineage and Cell class of Lung cells from Dropseq	HEG1 GIMAP8 SOSTDC1 TNS2 KDR	1.96e-05	195	75	5	304f0dc91bb57e98b0ca31d6bfb3ff9364e4da56
ToppCell	facs-Thymus-nan-3m-Lymphocytic-thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PRKD2 RAG2 RASGRP1 ZNF280D PATZ1	1.96e-05	195	75	5	79114b3c78cc15c413bb58f0673e7215b784a9b6
ToppCell	Smart-seq2-thymus_(Smart-seq2)-myeloid-myeloid_macrophage\|thymus_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	SIGLEC12 DST BAZ1B APLP2 ZYG11B	2.06e-05	197	75	5	e3349a381723393cd255f202afedd0c99037939b
ToppCell	Smart-seq2-thymus_(Smart-seq2)-myeloid-myeloid_macrophage-macrophage\|thymus_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	SIGLEC12 DST BAZ1B APLP2 ZYG11B	2.06e-05	197	75	5	e567886d69c6ea8dec87019c2ebc593793cb3107
ToppCell	tumor_Lung-Fibroblasts-COL13A1+_matrix_FBs\|Fibroblasts / Location, Cell class and cell subclass	DST MACF1 FHL1 PTGER4 ABCA8	2.06e-05	197	75	5	44f37a98f07c3e46a7e8fd3b64c2b2b44d5bbe40
ToppCell	18-Distal-Mesenchymal\|Distal / Age, Tissue, Lineage and Cell class	DST SOSTDC1 MACF1 FHL1 ABCA8	2.16e-05	199	75	5	d65150d2e24c40aa82712e7f034f6772102bd293
ToppCell	LPS_IL1RA-Endothelial-Endothelial\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	PRKD2 HEG1 DST MACF1 KDR	2.21e-05	200	75	5	72ea9882a8ed26fa1534aeb6ba0d1897dccc20c5
ToppCell	LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	DST GTF3C1 MACF1 FHL1 ABCA8	2.21e-05	200	75	5	9b0916d8d07ac2bf1739f7be5296bf77ffee6094
ToppCell	LPS_IL1RA-Endothelial\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	PRKD2 HEG1 DST MACF1 KDR	2.21e-05	200	75	5	5c092b2ecc081b5d04476c56333c338cd89ab984
ToppCell	LPS_only-Endothelial\|LPS_only / Treatment groups by lineage, cell group, cell type	PRKD2 HEG1 DST MACF1 KDR	2.21e-05	200	75	5	81e76508c9050d533853d5fd2f3097b27613d836
ToppCell	LPS_only-Endothelial-Endothelial\|LPS_only / Treatment groups by lineage, cell group, cell type	PRKD2 HEG1 DST MACF1 KDR	2.21e-05	200	75	5	4bb609a284d4e6066f17470a1736076aa4a1f84c
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_anti-infl-Z\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	SIGLEC8 VSIG1 DGKH ZNF90	6.30e-05	127	75	4	fbf7e6bea9991628e98f75c279e2992031dcb8db
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_aging_sig-Z\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	SIGLEC8 VSIG1 DGKH ZNF90	7.99e-05	135	75	4	9f9d0787a2e99207a9caa88a85565189ab8b940a
ToppCell	Tuft-tuft-3\|World / Class top	ZBTB40 DGKQ MAFF PTGER4	1.14e-04	148	75	4	f4f59b46a79fc9aa4c5d330a7b37b1a34a6d71cc
ToppCell	normal_Lymph_Node-Myeloid_cells-CD163+CD14+_DCs\|Myeloid_cells / Location, Cell class and cell subclass	PRKD2 SLC22A14 PATZ1 ZNF615	1.17e-04	149	75	4	a34d095b8e0fe59d69d84e4fd2fe4ccb82f92e4f
ToppCell	LPS_only-Lymphocytic_NKT-iNKT/MAIT-T-cells\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	KLRK1 GIMAP8 RSL24D1 ENOX2	1.23e-04	151	75	4	7270b8bbfae659e110bd9d513b602120b25de3dd
ToppCell	COVID-19_Mild-PLT_5\|World / Disease Group and Platelet Clusters	GIMAP8 VSIG1 DIP2C CPLANE1	1.26e-04	152	75	4	90ba4e8a735ec8921038fa072129535f0e3fd9ae
ToppCell	COVID-19_Severe-CD8+_T_naive\|World / disease group, cell group and cell class	ASIC1 ZNF541 ZNF639 GTSCR1	1.33e-04	154	75	4	b568417d88a78d8c46688847f0f5f4989bd36387
ToppCell	P28-Mesenchymal-mesenchymal_fibroblast-mesenchymal_progenitor_cell\|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	SOSTDC1 MAFF FHL1 SLC36A2	1.33e-04	154	75	4	44d4d99b08216c0901e3bc32743fa0a8b85b5149
ToppCell	COVID-19_Mild-Neu_0\|COVID-19_Mild / 5 Neutrophil clusters in COVID-19 patients	USP22 PPP4R1L ZNF280B	1.64e-04	63	75	3	1ab77b6f098686bc168427159282bbf3538d4292
ToppCell	E16.5-samps-Mesenchymal-Matrix_fibroblast-_fetal-Mature_Fibroblast_1\|E16.5-samps / Age Group, Lineage, Cell class and subclass	DTNA MACF1 FHL1 SLC36A2	1.65e-04	163	75	4	f1ec2625b52664308968b01d8e0275e1e0751480
ToppCell	E18.5-samps-Mesenchymal-Matrix_fibroblast-MatrixFB-A\|E18.5-samps / Age Group, Lineage, Cell class and subclass	DTNA MACF1 FHL1 SLC36A2	1.69e-04	164	75	4	519ab4fe885dfe4c50846f346a062acc2cb44299
ToppCell	facs-Large_Intestine-Distal-3m-Epithelial-enterocyte_of_epithelium_of_large_intestine\|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DGKH FHL1 IL22RA1 ENO3	1.85e-04	168	75	4	03896466698a79f7f1ad862cb7e05585260e2a5a
ToppCell	Mild/Remission-B_naive-4\|Mild/Remission / disease group and sub_cluster of B and Plasma cells(res = 0.5)	WHAMM MACF1 APLP2 DGKD	1.90e-04	169	75	4	c3a6179a64589a370108fea809b157839347759c
ToppCell	E17.5-Mesenchymal-developing_mesenchymal_cell-mesenchymal_immature_unknown_1\|E17.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	MACF1 KDR FHL1 SLC36A2	1.94e-04	170	75	4	7fa022471e14ac8a3bc147c793368a4d56a8e591
ToppCell	LPS-IL1RA-Lymphocytic_NKT-T_cells-T-cells\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	KLRK1 RASGRP1 GIMAP8 PTGER4	1.98e-04	171	75	4	539ea88acc6f948efdeae8b69e5c5ffaee29f1d9
ToppCell	E15.5-Endothelial-large_vessel_endothelial_cell-endothelial_cell_of_vein\|E15.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	PRKD2 DST GIMAP8 KDR	1.98e-04	171	75	4	3112d15f2a28cf4a71992db4971d960716dc1264
ToppCell	LPS-IL1RA-Lymphocytic_NKT-T_cells\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	KLRK1 RASGRP1 GIMAP8 PTGER4	2.03e-04	172	75	4	0fc692be845d4225ff8b63bf9195724fc8510c2c
ToppCell	droplet-Lung-nan-18m-Lymphocytic-Natural_Killer_T_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KLRK1 RASGRP1 GIMAP8 PTGER4	2.12e-04	174	75	4	5b00a795a9dd1a77305fcac5017cb276afdc1a27
ToppCell	droplet-Lung-nan-18m-Lymphocytic-mature_NK_T_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KLRK1 RASGRP1 GIMAP8 PTGER4	2.12e-04	174	75	4	3340b44c77f55244e3c2e2ea479d42563f937040
ToppCell	P03-Mesenchymal-developing_mesenchymal_cell-mesenchymal_immature_unknown_1\|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	MACF1 KDR FHL1 SLC36A2	2.17e-04	175	75	4	282f09bbdfa70d93b3f66591dcfb84c5ee0268c7
ToppCell	LPS-IL1RA+antiTNF-Lymphocytic_NKT\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	KLRK1 RASGRP1 GIMAP8 PTGER4	2.26e-04	177	75	4	f1efd9c3074d5635700fe7fbebf3dd0b1e0a84f1
ToppCell	368C-Myeloid-Macrophage-SPP1+_Macrophage_3\|Myeloid / Donor, Lineage, Cell class and subclass (all cells)	ADCK1 ZNF280C WRN UNK	2.31e-04	178	75	4	9d575902d3dbe33437c9d4200df093a741269803
ToppCell	3'-Parenchyma_lung-Endothelial-Lymphatic_EC-endothelial_cell_of_lymphatic_vessel-Lymphatic_EC_differentiating-Lymphatic_EC_differentiating_L.2.5.1.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	DST GIMAP8 MACF1 KDR	2.31e-04	178	75	4	ad3de3e03a401dac64431a541899445262246347
ToppCell	droplet-Lung-18m-Hematologic-lymphocytic-mature_NK_T_cell\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	KLRK1 RASGRP1 GIMAP8 PTGER4	2.31e-04	178	75	4	28bb1e3e447261d0cb47e2b6343b17b2d74db525
ToppCell	LPS_only-Lymphocytic_NKT-iNKT/MAIT\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	KLRK1 RASGRP1 HEG1 GIMAP8	2.36e-04	179	75	4	de3ddc1264e43727be50d69b81cc84a3c91812a2
ToppCell	LPS_only-Lymphocytic_NKT-iNKT/MAIT-iNKT-MAIT\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	KLRK1 RASGRP1 HEG1 GIMAP8	2.36e-04	179	75	4	def981e97e3ff9019910c9af3861ca0d08eb0d0f
ToppCell	Endothelial\|World / shred by cell class for turbinate	GIMAP8 KDR FHL1 ABCA8	2.36e-04	179	75	4	052b2681974be00efb8503fa4e2c85d91d5ebd06
ToppCell	droplet-Lung-18m-Hematologic-lymphocytic-mature_NK_T_cell-mature_NK_T_cell_l4\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	KLRK1 RASGRP1 GIMAP8 PTGER4	2.36e-04	179	75	4	ac0c257e63a5994282d8b350c1b517cc3fbee52a
ToppCell	390C-Fibroblasts-Fibroblast-G\|390C / Donor, Lineage, Cell class and subclass (all cells)	DST ASIC1 FHL1 ABCA8	2.41e-04	180	75	4	137fc14859c89e1ecd98bee388bb58c04b835847
ToppCell	Endothelial-A-HP_01\|World / lung cells shred on cell class, cell subclass, sample id	HEG1 GIMAP8 SOSTDC1 ZNF541	2.41e-04	180	75	4	4c3376169770ee9f9283daae44c17f35e46bfd19
ToppCell	390C-Fibroblasts-Fibroblast-G-\|390C / Donor, Lineage, Cell class and subclass (all cells)	DST ASIC1 FHL1 ABCA8	2.41e-04	180	75	4	cd6790de050151fedfa2c5ea6ad58b72665414b2
ToppCell	critical-Myeloid-Mast_cell\|Myeloid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	ZNF462 SIGLEC8 DIP2C FHL1	2.46e-04	181	75	4	f0d81ae74d3f32979624a94b2ef93774831a7970
ToppCell	10x3'2.3-week_12-13-Myeloid_neutrophil-granulo-eo/baso/mast-basophil\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	SIGLEC12 SIGLEC8 DGKQ TCEANC	2.57e-04	183	75	4	f9a3af96c0fb7d5c4d7df6db8b2c42e322418c08
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1-6_LAMP5_CA13_(Lamp5_Lhx6_1)\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	HEG1 DGKD KDR LRIT1	2.62e-04	184	75	4	ae0a77e3e520a246b17776bb19503519636b02ee
ToppCell	Control-Lymphocytic_NKT\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	KLRK1 RASGRP1 GIMAP8 PTGER4	2.68e-04	185	75	4	59d68e119f58b35bab36294758f6b2e25fd8f5c0
ToppCell	PND10-Endothelial-Endothelial_blood-vessel-Macrovascular_EC-AEC-AEC_prolif\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	HEG1 DST USP22 ZNF280C	2.68e-04	185	75	4	87151ab95530e70d61328b336518df58db584acb
ToppCell	Smart-seq2-spleen_(Smart-seq2)-lymphocytic-innate_lymphocytic\|spleen_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	KLRK1 HEG1 GTF3C1 MAFF	2.73e-04	186	75	4	fc0b488c201a32d829047b58460297df2818b45d
ToppCell	ILEUM-inflamed-(8)_Fibroblast-(8)_Smooth_muscle_cells\|(8)_Fibroblast / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	DTNA SOSTDC1 APLP2 FHL1	2.73e-04	186	75	4	cacc2f0b2ed46516173b61ba1c5c226a2db7cddc
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	ZNF462 DIP2C DGKH SLC36A2	2.79e-04	187	75	4	9d77ca45f7563bd6f2a0c1be5d99d93ad30983f7
ToppCell	Smart-seq2-spleen_(Smart-seq2)-lymphocytic-innate_lymphocytic-mature_NK_T_cell\|spleen_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	KLRK1 HEG1 GTF3C1 MAFF	2.79e-04	187	75	4	6981b856187a2e689260ecb7d0a1193a374ee9b9
ToppCell	wk_08-11-Endothelial-Blood_vessel_endothelial-GRIA2+_arterial_endo\|wk_08-11 / Celltypes from embryonic and fetal-stage human lung	HEG1 GIMAP8 DGKI KDR	2.79e-04	187	75	4	a27aa97aa6508a3ffe92c2b6bb0511a95650a390
ToppCell	5'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.2.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	VSIG1 DGKD ENO1 SLC36A2	2.85e-04	188	75	4	2b8d70f761eda5509f21845a87cdb3602a639dd7
ToppCell	moderate-Epithelial-Ionocyte\|Epithelial / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	DST DTNA SOSTDC1 DGKI	2.90e-04	189	75	4	6011b747e27d61d222380a7bffdd921a68e9b657
ToppCell	(5)_Fibroblasts-(5)_Fibroblast-C_(Myofibroblast)\|(5)_Fibroblasts / Lung cell shreds - cell class (v4) and cell subclass (v4)	DST MACF1 FHL1 PTGER4	2.96e-04	190	75	4	71e112dfb8c3190fe0286b45a046ea789eb6a8db
ToppCell	PCW_13-14\|World / Celltypes from embryonic and fetal-stage human lung	DST SOSTDC1 MACF1 ABCA8	2.96e-04	190	75	4	62a3ec1ae0829602b0569cc051210551644f1d46
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_ILC-NK_cell-NK_c01-FCGR3A\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	KLRK1 ZNF462 ZNF280B MAFF	2.96e-04	190	75	4	600b9674197f743dea1d19d3df0fc993b6e6aa25
ToppCell	PND01-03-samps-Mesenchymal-Matrix_fibroblast-MatrixFB-A\|PND01-03-samps / Age Group, Lineage, Cell class and subclass	DTNA MACF1 FHL1 SLC36A2	3.02e-04	191	75	4	e7c605b56934d1383237c1f946dbccef25d91368
ToppCell	PBMC-Severe-Myeloid-cDC-cDC-cDC_5\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	DST DTNA MAFF PTGER4	3.02e-04	191	75	4	92c5a26b90a55831039220341d863cf2940f3c9b
ToppCell	PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Lymphocytic-Lymphocytic_T-CD8-positive,_mature_gamma-delta_T_cell\|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k)	KLRK1 RASGRP1 GTF3C1 MACF1	3.08e-04	192	75	4	ce867b6e78c1d8f30dff81bf572a78a897bc7625
ToppCell	PBMC-Severe-Myeloid-cDC-cDC-cDC_5\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	DST DTNA MAFF PTGER4	3.08e-04	192	75	4	6184163dbfca882824cb266bb9030d9f79e3acb0
ToppCell	PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Lymphocytic-Lymphocytic_T-CD8-positive,_mature_gamma-delta_T_cell-T_gdT_c14-TRDV2\|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k)	KLRK1 RASGRP1 GTF3C1 MACF1	3.08e-04	192	75	4	58a7829b411b02b422ef75e2277a868969cc23e8
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive\|renal_cortex_nuclei / Celltypes from Cells and Nuclei per compartment and clinical group	DTNA MACF1 DGKD DGKH	3.08e-04	192	75	4	8b86db2ebe0199fee0e9800566a619a24bfdeed5
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_ILC-NK_cell\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	KLRK1 ZNF462 ZNF280B MAFF	3.08e-04	192	75	4	c5f77c2103841505d13e09173549811312ef2f01
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_ILC\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	KLRK1 ZNF462 ZNF280B MAFF	3.08e-04	192	75	4	e981162f387a31111c0ae8355dbe9db5785c4838
ToppCell	facs-BAT-Fat-3m-Endothelial-nan\|BAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DST TNS2 APLP2 KDR	3.14e-04	193	75	4	e340064cd146deac03f2d0fd43e2e218bb6057c9
ToppCell	Control-Lymphoid_T/NK-Treg\|Control / Disease group, lineage and cell class	RASGRP1 VSIG1 DGKH GTSCR1	3.14e-04	193	75	4	715f2bbee12a7952cba85d9cd8820411983ce790
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	HEG1 DST MACF1 FHL1	3.14e-04	193	75	4	b3ad5ff480d99217f36cc7471e5a96a519ddb409
ToppCell	ILEUM-inflamed-(8)_Smooth_muscle_cells\|inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	DST DTNA SOSTDC1 FHL1	3.14e-04	193	75	4	084c88f08ce0ecd6c9f4334caed370eb2154f896
ToppCell	Control-Stromal-Myofibroblast\|Stromal / Disease state, Lineage and Cell class	DST DTNA MACF1 FHL1	3.14e-04	193	75	4	5896242f713ae5fd1a4ebb63827f15d7279dced2
ToppCell	facs-BAT-Fat-3m-Endothelial-endothelial_cell\|BAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DST TNS2 APLP2 KDR	3.14e-04	193	75	4	a211b386fd0fb9da9937361d29d90925a72c9715
ToppCell	facs-BAT-Fat-3m-Endothelial\|BAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DST TNS2 APLP2 KDR	3.14e-04	193	75	4	3086c33f4d6fab66966818737f95ae4d6b2615b0
ToppCell	droplet-Kidney-KIDNEY-1m\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DST SOSTDC1 TNS2 APLP2	3.21e-04	194	75	4	837cee7e6147d92a2f4b86f1ed761a9bfe65b61d
ToppCell	facs-Lung-nan-3m-Endothelial-endothelial_cell_of_lung\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HEG1 APLP2 KDR DGKH	3.21e-04	194	75	4	f159ef8541d75a4e98468947f231bb463bec922c
ToppCell	LPS-IL1RA-Endothelial\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	HEG1 DST KDR DGKH	3.21e-04	194	75	4	43f92b0533e26633dc94cce554045d641ef8fd76
ToppCell	PBMC-Control-Lymphocyte-T/NK-CD4+_T-Treg\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	RASGRP1 VSIG1 DGKH GTSCR1	3.21e-04	194	75	4	2faf49d85d09932c9c20d9f675c8093ad802fae5
ToppCell	PBMC-Control-Lymphocyte-T/NK-CD4+_T-Treg\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	RASGRP1 VSIG1 DGKH GTSCR1	3.21e-04	194	75	4	fd3d5ac94de3db7136684c86f8589631ad87e6d8
ToppCell	LPS-IL1RA-Endothelial-Endothelial\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	HEG1 DST KDR DGKH	3.21e-04	194	75	4	1d39d968730a7e85b6161c1c8a6bd38afe9bcad7
ToppCell	LAM-Endothelial\|LAM / Condition, Lineage and Cell class	HEG1 GIMAP8 SOSTDC1 KDR	3.21e-04	194	75	4	1241e3e75414b619abc9431627619f5c194ec930
ToppCell	5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts-Alveolar_fibroblasts_L.2.1.1.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	DST MACF1 FHL1 ABCA8	3.27e-04	195	75	4	df409f94f4e83be89f7a608058ee07ce3ce3a149
ToppCell	facs-Aorta-Heart-3m-Endothelial\|Aorta / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HEG1 GIMAP8 MACF1 KDR	3.27e-04	195	75	4	8493f2f60fc356af28b9c0e287d4cd8c8899c081
ToppCell	Adult-Mesenchymal-matrix_fibroblast_1_cell\|Adult / Lineage, Cell type, age group and donor	DST DTNA FHL1 ABCA8	3.27e-04	195	75	4	61c9e09fc84d1012e472185d70ad0a06cee30d6e
ToppCell	COVID-19-Fibroblasts-Alveolar_FB\|COVID-19 / group, cell type (main and fine annotations)	DST DTNA FHL1 ABCA8	3.27e-04	195	75	4	603050beeb33c331d4b2e3fa46cae3f3e0e4bdc7
ToppCell	5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	DST MACF1 FHL1 ABCA8	3.27e-04	195	75	4	4243190ad291d56694e2155954dbaa879c9d3844
ToppCell	facs-Lung-nan-3m-Endothelial\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HEG1 APLP2 KDR DGKH	3.27e-04	195	75	4	7f9b7f15006610ad591063d90e90367bd6083c7f
Drug	1-stearoyl-2-arachidonoyl-sn-glycerol	PRKD2 RASGRP1 DGKQ DGKI DGKD DGKH	3.10e-09	40	73	6	CID000001398
Drug	C-1b	PRKD2 RASGRP1 DGKQ DGKI DGKD DGKH	1.16e-07	72	73	6	CID006102740
Drug	AC1L4Q08	DGKQ DGKI DGKD DGKH	1.29e-07	15	73	4	CID000161747
Drug	C-1A	PRKD2 RASGRP1 DGKQ DGKI DGKD DGKH	4.74e-07	91	73	6	CID009543473
Drug	1,2-dicaprin	PRKD2 DGKQ DGKI DGKD DGKH	5.04e-07	49	73	5	CID000001321
Drug	diradylglycerol	PRKD2 DGKQ DGKI DGKD DGKH	6.17e-07	51	73	5	CID006437874
Drug	R59949	PRKD2 DGKQ DGKI DGKD DGKH	3.03e-06	70	73	5	CID000657356
Drug	R59022	PRKD2 DGKQ DGKI DGKD DGKH	4.56e-06	76	73	5	CID000003012
Drug	DiC8	PRKD2 RASGRP1 DGKQ DGKI DGKD DGKH	7.50e-06	146	73	6	CID000001323
Drug	1,3-diolein	PRKD2 DGKQ DGKI DGKD DGKH	1.05e-05	90	73	5	CID000033120
Drug	1,3-DCG	PRKD2 DGKQ DGKI DGKD DGKH	1.30e-05	94	73	5	CID000150911
Drug	AMP group	PRKD2 DST UBE2G1 DGKQ DGKI DGKD DGKH PTGER4 ENO1 ENO3	1.54e-05	579	73	10	CID000000224
Drug	(S)-1,2-Diolein	PRKD2 DGKQ DGKI DGKD	2.00e-05	50	73	4	CID000001324
Drug	monoelaidin	DGKQ DGKI DGKD DGKH	2.00e-05	50	73	4	CID000033022
Drug	RHC 80267	PRKD2 DGKQ DGKI DGKD DGKH	3.03e-05	112	73	5	CID000005063
Drug	N-succinylphenylglycine	ENO1 ENO3	3.04e-05	3	73	2	CID000448582
Drug	C04309	ENO1 ENO3	3.04e-05	3	73	2	CID000440293
Drug	AC1MOUJL	ENO1 ENO3	3.04e-05	3	73	2	CID003400924
Drug	2,3-diketo-1-phosphohexane	ENO1 ENO3	3.04e-05	3	73	2	CID000192519
Drug	C03356	ENO1 ENO3	3.04e-05	3	73	2	CID000439988
Drug	3-bromo-2-(bromomethyl)propionic acid	ENO1 ENO3	3.04e-05	3	73	2	CID000318915
Drug	Harmol hydrochloride monohydrate [40580-83-4]; Down 200; 15.8uM; MCF7; HT_HG-U133A	DTNA ZBTB40 DIP2C FHL1 ZNF639 ENOX2	3.75e-05	194	73	6	2900_DN
Drug	Tetracaone hydrochloride [136-47-0]; Down 200; 13.2uM; MCF7; HT_HG-U133A	BAZ2A SLC22A14 TNS2 FHL1 ZC3H3 ZNF639	3.97e-05	196	73	6	2888_DN
Drug	Ifenprodil tartrate [23210-58-4]; Down 200; 8.4uM; MCF7; HT_HG-U133A	PRKD2 DTNA ZBTB40 APLP2 ZC3H3 ZNF639	4.09e-05	197	73	6	5463_DN
Drug	Mexiletine hydrochloride [5370-01-4]; Down 200; 18.6uM; HL60; HT_HG-U133A	ZBTB7A BAZ2A DTNA MACF1 MAFF ZC3H3	4.21e-05	198	73	6	2364_DN
Drug	(+) -Levobunolol hydrochloride [47141-41-3]; Up 200; 12.2uM; MCF7; HT_HG-U133A	ASIC1 SLC22A14 DGKQ FHL1 ENO3 ENOX2	4.21e-05	198	73	6	4980_UP
Drug	Tropine [120-29-6]; Up 200; 28.4uM; PC3; HT_HG-U133A	BAZ2A ASIC1 DTNA CPLANE1 SUV39H2 ZNF639	4.33e-05	199	73	6	5790_UP
Drug	Prilocaine hydrochloride [1786-81-8]; Up 200; 15.6uM; MCF7; HT_HG-U133A	ASIC1 MAFF FHL1 PTGER4 ENO3 ENOX2	4.33e-05	199	73	6	4749_UP
Drug	Sulfisoxazole [127-69-5]; Up 200; 15uM; HL60; HG-U133A	DTNA PATZ1 ZBTB40 DIP2C MACF1 ENOX2	4.33e-05	199	73	6	1603_UP
Drug	Haloperidol [52-86-8]; Down 200; 10.6uM; HL60; HG-U133A	PRKD2 GTF3C1 BAZ2A DGKD MAFF ENOX2	4.45e-05	200	73	6	2039_DN
Drug	dimethyl chlorophosphate	ENO1 ENO3	6.06e-05	4	73	2	CID000101863
Drug	2-ptz	ENO1 ENO3	6.06e-05	4	73	2	CID000445375
Drug	[2-(oxidoamino)-2-oxoethyl]phosphonic acid	ENO1 ENO3	6.06e-05	4	73	2	CID011969443
Drug	3-aminoenolpyruvate-2-phosphate	ENO1 ENO3	6.06e-05	4	73	2	CID003037152
Drug	tricyclohexylammonium	ENO1 ENO3	6.06e-05	4	73	2	CID000226271
Drug	N-methylacrylamide	ENO1 ENO3	1.01e-04	5	73	2	CID000014471
Drug	2-phospho-3-butenoic acid	ENO1 ENO3	1.01e-04	5	73	2	CID000191423
Drug	AC1L1CAI	ENO1 ENO3	1.01e-04	5	73	2	CID000000145
Drug	1-Pdmsp	ENO1 ENO3	1.01e-04	5	73	2	CID000000561
Drug	tartronate semialdehyde phosphate	ENO1 ENO3	1.01e-04	5	73	2	CID000151938
Drug	PDBu	PRKD2 RASGRP1 DGKQ DGKI DGKD DGKH	1.49e-04	249	73	6	CID000037783
Drug	dimidium	ENO1 ENO3	1.51e-04	6	73	2	CID000068207
Drug	Z(2-Cl)-OSu	ENO1 ENO3	1.51e-04	6	73	2	CID000580665
Drug	4-(N,N-dimethylamino)cinnamoyl-CoA	ENO1 ENO3	1.51e-04	6	73	2	CID000445461
Drug	CPEP	ENO1 ENO3	2.11e-04	7	73	2	CID000360637
Drug	N-tert-butylacrylamide	ENO1 ENO3	2.11e-04	7	73	2	CID000007877
Drug	glycidol phosphate	ENO1 ENO3	2.11e-04	7	73	2	CID000152659
Drug	lavendustin C6	ENO1 ENO3	2.11e-04	7	73	2	CID000126839
Drug	AC1L1BDQ	PRKD2 DGKQ DGKI DGKD DGKH	2.37e-04	173	73	5	CID000001394
Drug	triphosphoinositide	PRKD2 ASIC1 DGKQ DGKI DGKD DGKH	2.44e-04	273	73	6	CID009543520
Drug	1,2-diglyceride	PRKD2 DGKQ DGKI DGKD DGKH	2.49e-04	175	73	5	CID000192866
Drug	17-AAG; Up 200; 1uM; MCF7; HT_HG-U133A_EA	PRKD2 BAZ2A DTNA ZBTB40 DIP2C	2.49e-04	175	73	5	1006_UP
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	ZBTB7A RASGRP1 DTNA PATZ1 ENOX2	2.56e-04	176	73	5	1535_DN
Drug	Cortisporin	PRKD2 RAG2 DGKQ DGKI DGKD	2.63e-04	177	73	5	CID000004454
Drug	prochlorperazine dimaleate salt; Up 200; 10uM; MCF7; HT_HG-U133A	ASIC1 DTNA ZBTB40 BAZ1B MAFF	2.77e-04	179	73	5	1640_UP
Drug	macrophomate	ENO1 ENO3	2.80e-04	8	73	2	CID010889109
Drug	Ticlopidine hydrochloride [53885-35-1]; Up 200; 13.4uM; MCF7; HT_HG-U133A	RASGRP1 DTNA SIGLEC8 BAZ1B MAFF	3.07e-04	183	73	5	1475_UP
Drug	Naringenine [480-41-1]; Down 200; 14.6uM; MCF7; HT_HG-U133A	ZBTB7A DTNA BAZ1B TNS2 FHL1	3.39e-04	187	73	5	3278_DN
Drug	Betulinic acid [472-15-1]; Up 200; 8.8uM; MCF7; HT_HG-U133A	DTNA PATZ1 BAZ1B MAFF ENO3	3.47e-04	188	73	5	3281_UP
Drug	Ivermectin [70288-86-7]; Up 200; 4.6uM; MCF7; HT_HG-U133A	BAZ1B DGKQ MAFF FHL1 ZNF639	3.56e-04	189	73	5	7206_UP
Drug	Methoxy-6-harmalan [3589-73-9]; Up 200; 18.6uM; MCF7; HT_HG-U133A	RAG2 ZBTB7A DTNA MAFF ZNF639	3.56e-04	189	73	5	5455_UP
Drug	retinoic acid; Down 200; 1uM; MCF7; HT_HG-U133A	HEG1 DTNA BAZ1B TNS2 ZC3H3	3.56e-04	189	73	5	5208_DN
Drug	AC1L19IJ	ENO1 ENO3	3.60e-04	9	73	2	CID000000562
Drug	AC1L1A4W	ENO1 ENO3	3.60e-04	9	73	2	CID000000837
Drug	0317956-0000 [391210-11-0]; Down 200; 10uM; MCF7; HT_HG-U133A	ZBTB7A RASGRP1 HEG1 ZBTB40 MAFF	3.73e-04	191	73	5	3855_DN
Drug	sodium tripolyphosphate	SIGLEC12 ENO1 ENO3	3.81e-04	44	73	3	CID000024455
Drug	AC1OAGKW	RAG2 DGKQ DGKI DGKD DGKH	3.91e-04	193	73	5	CID006857413
Drug	Chlortetracycline hydrochloride [64-72-2]; Down 200; 7.8uM; HL60; HG-U133A	GTF3C1 BAZ2A ZBTB40 MAFF ZC3H3	4.01e-04	194	73	5	2042_DN
Drug	Spiramycin [8025-81-8]; Down 200; 4.8uM; MCF7; HT_HG-U133A	PRKD2 DTNA ZBTB40 ZC3H3 SUV39H2	4.01e-04	194	73	5	3419_DN
Drug	Mevalonic-D, L acid lactone [674-26-0]; Down 200; 30.8uM; MCF7; HT_HG-U133A	PATZ1 ZBTB40 TNS2 FHL1 ZC3H3	4.10e-04	195	73	5	3459_DN
Drug	Nefopam hydrochloride [23327-57-3]; Down 200; 13.8uM; HL60; HT_HG-U133A	ZNF280D BAZ2A DTNA MACF1 FHL1	4.10e-04	195	73	5	2355_DN
Drug	Methoxamine hydrochloride [61-16-5]; Up 200; 16.2uM; MCF7; HT_HG-U133A	BAZ2A DTNA BAZ1B APLP2 MAFF	4.10e-04	195	73	5	4972_UP
Drug	Iressa; Down 200; 10uM; HL60; HG-U133A	UBE2G1 GTF3C1 BAZ2A DTNA BAZ1B	4.10e-04	195	73	5	541_DN
Drug	estradiol, USP; Up 200; 0.1uM; HL60; HT_HG-U133A	BAZ2A SOSTDC1 FHL1 PTGER4 SUV39H2	4.10e-04	195	73	5	2668_UP
Drug	Karakoline [39089-30-0]; Up 200; 10.6uM; MCF7; HT_HG-U133A	BAZ2A FHL1 CPLANE1 ZNF639 ENOX2	4.10e-04	195	73	5	4763_UP
Drug	Piracetam [7491-74-9]; Down 200; 28.2uM; MCF7; HT_HG-U133A	PRKD2 BAZ2A PATZ1 MACF1 ZNF639	4.20e-04	196	73	5	5462_DN
Drug	Acyclovir [59277-89-3]; Down 200; 17.8uM; HL60; HG-U133A	BAZ2A ZBTB40 BAZ1B MAFF ENOX2	4.20e-04	196	73	5	2044_DN
Drug	estradiol, USP; Down 200; 0.1uM; MCF7; HT_HG-U133A	BAZ2A ASIC1 TNS2 APLP2 ZNF639	4.20e-04	196	73	5	5568_DN
Drug	(-)-Cinchonidine [485-71-2]; Down 200; 13.6uM; PC3; HT_HG-U133A	PRKD2 ZBTB7A HEG1 BAZ1B TNS2	4.20e-04	196	73	5	5833_DN
Drug	radicicol; Down 200; 0.1uM; MCF7; HT_HG-U133A	DTNA PATZ1 MAFF ENO1 ENOX2	4.20e-04	196	73	5	5947_DN
Drug	(-)-Quinpirole hydrochloride [85760-74-3]; Up 200; 15.6uM; MCF7; HT_HG-U133A	HEG1 DTNA PATZ1 TNS2 ENO3	4.20e-04	196	73	5	3539_UP
Drug	Diltiazem hydrochloride [33286-22-5]; Down 200; 8.8uM; PC3; HG-U133A	WRN MACF1 APLP2 MAFF FHL1	4.20e-04	196	73	5	1948_DN
Drug	Piperidolate hydrochloride [129-77-1]; Down 200; 11.2uM; MCF7; HT_HG-U133A	DTNA WRN TNS2 FHL1 SUV39H2	4.20e-04	196	73	5	6772_DN
Drug	Piribedil hydrochloride [78213-63-5]; Up 200; 12uM; HL60; HT_HG-U133A	HEG1 ZNF280B FHL1 IL22RA1 ENO3	4.20e-04	196	73	5	2951_UP
Drug	Bambuterol hydrochloride [81732-46-9]; Down 200; 10uM; MCF7; HT_HG-U133A	ZBTB7A SLC22A14 DTNA MAFF ENO3	4.20e-04	196	73	5	3199_DN
Drug	Metoclopramide monohydrochloride [7232-21-5]; Up 200; 11.8uM; MCF7; HT_HG-U133A	BAZ2A ASIC1 MAFF FHL1 ZC3H3	4.20e-04	196	73	5	4750_UP
Drug	Amikacin hydrate [37517-28-5]; Down 200; 6.6uM; MCF7; HT_HG-U133A	ZBTB7A ZNF280D ASIC1 SLC22A14 BAZ1B	4.20e-04	196	73	5	3233_DN
Drug	Mifepristone [84371-65-3]; Down 200; 9.4uM; HL60; HG-U133A	ZBTB7A BAZ2A ASIC1 DTNA DGKD	4.20e-04	196	73	5	1569_DN
Drug	radicicol; Down 200; 0.1uM; MCF7; HG-U133A	BAZ2A ASIC1 TNS2 DGKD MAFF	4.20e-04	196	73	5	325_DN
Drug	cox-2 inhibitor I; Down 200; 10uM; MCF7; HG-U133A	BAZ2A DTNA ZBTB40 MAFF ENOX2	4.20e-04	196	73	5	253_DN
Drug	Sulfisoxazole [127-69-5]; Down 200; 15uM; MCF7; HT_HG-U133A	ZBTB7A DTNA BAZ1B DGKD ZNF639	4.20e-04	196	73	5	5257_DN
Drug	Molindone hydrochloride [15622-65-8]; Up 200; 12.8uM; PC3; HT_HG-U133A	BAZ2A DTNA ZNF280B PTGER4 ZNF639	4.30e-04	197	73	5	4199_UP
Drug	estradiol, USP; Down 200; 0.1uM; HL60; HT_HG-U133A	PRKD2 PATZ1 TNS2 MAFF ENOX2	4.30e-04	197	73	5	2668_DN
Drug	Guanabenz acetate [23256-50-0]; Up 200; 13.8uM; MCF7; HT_HG-U133A	BAZ2A ASIC1 DTNA SIGLEC8 FHL1	4.30e-04	197	73	5	5703_UP
Drug	Nifenazone [2139-47-1]; Down 200; 13uM; MCF7; HT_HG-U133A	ZNF280D DTNA BAZ1B APLP2 FHL1	4.30e-04	197	73	5	2285_DN
Drug	Liothyronine [6893-02-3]; Down 200; 6.2uM; HL60; HT_HG-U133A	BAZ2A DTNA MACF1 ZC3H3 ENO3	4.30e-04	197	73	5	2984_DN
Drug	Cefepime hydrochloride [123171-59-5]; Up 200; 7.4uM; MCF7; HT_HG-U133A	RAG2 HEG1 MAFF CPLANE1 ZNF639	4.30e-04	197	73	5	3581_UP
Drug	Arecoline hydrobromide [300-08-3]; Up 200; 17uM; MCF7; HT_HG-U133A	BAZ2A ASIC1 SIGLEC8 SUV39H2 ENO3	4.30e-04	197	73	5	2657_UP
Drug	Cinnarizine [298-57-7]; Up 200; 10.8uM; MCF7; HT_HG-U133A	ZBTB7A ZNF280D ASIC1 DTNA MAFF	4.30e-04	197	73	5	7174_UP
Drug	Kynurenine, 3-hydroxy (R,S) [2147-61-7]; Up 200; 17.8uM; MCF7; HT_HG-U133A	ASIC1 SIGLEC8 KDR FHL1 ZNF639	4.30e-04	197	73	5	5641_UP
Disease	sialic acid-binding Ig-like lectin 6 measurement	SIGLEC12 SIGLEC8	1.54e-04	8	70	2	EFO_0008285
Disease	cystitis (implicated_via_orthology)	KDR PTGER4	1.54e-04	8	70	2	DOID:1679 (implicated_via_orthology)
Disease	chronic lymphocytic leukemia	PRKD2 ZBTB7A ZNF280D RFX7	1.88e-04	119	70	4	EFO_0000095
Disease	cerebellum white matter volume change measurement, age at assessment	DGKH ABCA8	1.03e-03	20	70	2	EFO_0008007, EFO_0021498
Disease	thalamus volume	ZNF280D MACF1 RFX7	1.10e-03	85	70	3	EFO_0006935
Disease	Adenocarcinoma of lung (disorder)	PRKD2 KDR IPO4 ENO1	1.48e-03	206	70	4	C0152013
Disease	migraine disorder	ZNF462 DIP2C BAZ1B MACF1 SUV39H2	1.60e-03	357	70	5	MONDO_0005277
Disease	S-6-hydroxywarfarin measurement	DTNA DIP2C LIPK CHCHD2P9 ZC3H3	1.83e-03	368	70	5	EFO_0803326

Protein segments in the cluster

Peptide	Gene	Start	Entry
QCSKCRLQFLTFKEK	ZNF280B	461	Q86YH2
RCTKCRLQFLTCKEK	ZNF280D	476	Q6N043
RCCIRALAEHKKKNT	ADCK1	466	Q86TW2
SAENARCKVCRKKGE	BAZ1B	1181	Q9UIG0
EKSVNKVTCLVCRKG	BAZ2A	1671	Q9UIF9
KQCKDLVVFECKKRA	RASGRP1	581	O95267
KRKFCAVCRKVLEAP	DGKQ	131	P52824
SIVCKNNKKVTFRCT	RAG2	111	P55895
KCRIFTRSDKCKVVI	RAD9B	106	Q6WBX8
CRRDKKQCKSRFVTP	APLP2	116	Q06481
KQCKSRFVTPFKCLV	APLP2	121	Q06481
ASCRVKRVCQKEELQ	MAFF	66	Q9ULX9
RKHRFCTDCKNKVLR	GGNBP2	211	Q9H3C7
EVTRQVAKCKCAKRF	DST	7281	Q03001
VAKCKCAKRFQVEQI	DST	7286	Q03001
CGEIIAIRKSKKNFC	ENOX2	151	Q16206
VARKKQQKALSTCVC	OR51T1	231	Q8NGJ9
VLSKAIEKIKCLFCR	PTGER4	336	P35408
KQRCPVVKSKCRENA	KLRK1	36	P26718
DEVTRQVAQCKCAKR	MACF1	3251	O94854
KDCKFNCHKRCATRV	PRKD2	296	Q9BZL6
TCCRKNKNDISKLIF	HEG1	1271	Q9ULI3
CEVCKFKAHKRCAVR	DGKH	206	Q86XP1
ALQKRCRKCFNKDST	LRIT1	551	Q9P2V4
CVCRIFKIQVRNTVK	GTSCR1	91	Q86UQ5
TRKQVACEICGKIFR	PATZ1	351	Q9HBE1
VAKDNKILCNKCTTR	FHL1	81	Q13642
KRIAKAVNEKSCNCL	ENO1	326	P06733
IKLCEDFSKVLKQCR	CHCHD2P9	131	Q5T1J5
SIKTRRCIFKAIQCN	CPLANE1	1711	Q9H799
FAKSALRRKCAVCKI	DGKI	201	O75912
CKKRFSISLACEKIR	POLQ	1846	O75417
FKKCGRRVCAFNNKE	GIMAP8	591	Q8ND71
VCQYKAKVACVKSRD	DIP2C	581	Q9Y2E4
VCKFKAHKRCAVRAT	DGKD	196	Q16760
RTACKLRFVQKKCNL	DTNA	36	Q9Y4J8
VAKKGCQRITRKSCN	IL22RA1	66	Q8N6P7
KRIAQAVEKKACNCL	ENO3	326	P13929
KKVTRASVLDFCKNR	SLC22A14	361	Q9Y267
RILCCLTFLVKVKSK	IPO4	266	Q8TEX9
CGDRKLFQVRKVCAA	PPP4R1L	171	Q9P1A2
ESQSCKIDKTQRKRC	NR5A1	51	Q13285
KIDKTQRKRCPFCRF	NR5A1	56	Q13285
ISACVSRCVQKALKK	GFM2	666	Q969S9
ERKKCVICQDQSKTV	RNF26	376	Q9BY78
VKCAQRFCKRLNKPF	SLC36A2	106	Q495M3
SFCIIFIIVRSCRKK	SIGLEC8	376	Q9NYZ4
CAKRASLRSRKDQCK	WHAMM	476	Q8TF30
VQNKRCAVEERKACV	WRN	21	Q14191
CAVEERKACVRKSVF	WRN	26	Q14191
CIIFVVVRSCRKKSA	SIGLEC12	496	Q96PQ1
KNKIATRNVSFCVRK	ABCA8	1301	O94911
CRRGKCQKEAKRSSA	ASIC1	466	P78348
CNECDKTFRKKTCLI	ZNF615	626	Q8N8J6
ACIRKAKISAVAFRK	ZYG11B	86	Q9C0D3
AEARKRKAKSCICHV	USP22	51	Q9UPT9
KVAVCTRFVRGTCKK	ZC3H3	696	Q8IXZ2
CEVCGVRFTRNDKLK	ZBTB7B	376	O15156
KHKRTDSNVCRVCKE	ZNF639	226	Q9UID6
ISVVCFARNKAKAKA	VSIG1	251	Q86XK7
KCRRCEKYNCKVTVI	TCEANC	296	Q8N8B7
KKRVRTVCKCGAVTC	SUV39H2	391	Q9H5I1
CNDRLGKKVRVKCNT	UBL5	6	Q9BZL1
FVRNDCKVFRFCKSK	RSL24D1	21	Q9UHA3
IEIKATKVCDQRTKC	RFX7	491	Q2KHR2
TKVCDQRTKCKSRCN	RFX7	496	Q2KHR2
KITVVTACKCKRYTR	SOSTDC1	156	Q6X4U4
KCQECDKVFKRSSAL	ZNF90	426	Q03938
RRAVEKKKCSLCSFQ	ZNF462	1761	Q96JM2
VCLAQDRKTKKRHCV	KDR	641	P35968
FKCFSCSKVLKNNIR	ZNF280C	316	Q8ND82
QKRKIFTNKCERAGC	ZFAND2B	91	Q8WV99
STKCCKKSIVRLVRN	GTF3C1	651	Q12789
SVKCLKCQEQKRAVL	UNK	766	Q9C0B0
GEFKRKVARCVRKSQ	UBE2G1	151	P62253
RVCKVATHRKCEAKV	TNS2	61	Q63HR2
IRAKAFQKCPICEKV	ZBTB7A	376	O95365
KRCRVAKSKQVQCKE	ZBTB40	756	Q9NUA8
RKHVCKICSKAFKRQ	ZNF541	166	Q9H0D2
IATKVCNRKLFRRIC	LIPK	241	Q5VXJ0